Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy

Cardiovascular Research

Volumn 79, Issue 3, 2008, Pages 472-480

  Birks, Emma J ^a   Latif, Najma ^a   Enesa, Karine ^b   Folkvang, Tonje ^b   Luong, Le Anh ^b   Sarathchandra, Padmini ^a   Khan, Mak ^a   Ovaa, Huib ^c   Terracciano, Cesare M ^a   Barton, Paul J R ^a   Yacoub, Magdi H ^a   Evans, Paul C ^b  

^a HAREFIELD HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Apoptosis; Caspases; Dilated cardiomyopathy; p53; Ubiquitin proteasome system

Indexed keywords

CASPASE 3; CASPASE 9; CASPASE ACTIVATED DEOXYRIBONUCLEASE; CHYMOTRYPSIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEASOME; PROTEIN MDM2; PROTEIN P53; UBIQUITIN;

ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DNA FRAGMENTATION; ENZYME ACTIVATION; FEMALE; HEART; HEART FAILURE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UBIQUITINATION; WESTERN BLOTTING;

ADULT; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARDIOMYOPATHY, DILATED; CASPASE 3; CASPASE 9; DEOXYRIBONUCLEASES; DNA FRAGMENTATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; POLY(ADP-RIBOSE) POLYMERASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN; UBIQUITIN THIOLESTERASE; UP-REGULATION; YOUNG ADULT;

EID: 48749126678     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn083     Document Type: Article

References (39)

1. Song H, Conte JV, Foster AH, McLaughlin JS, Wei CM. Increased p53 protein expression in human failing myocardium. J Heart Lung Transplant 1999;18:744-749.
2. Song H, Ren SX, Xia F, Zhang RW, Wei CM. Expression of p53 protein in human cardiac tissue with congestive heart failure. FASEB J 1997;11:2867.
3. Regula KM, Kirshenbaum LA. p53 activates the mitochondrial death pathway and apoptosis of ventricular myocytes independent of de novo gene transcription. J Mol Cell Cardiol 2001;33:1435-1445.
4. Ikeda S, Hamada M, Hiwada K. Cardiomyocyte apoptosis with enhanced expression of p53 and Bax in right ventricle after pulmonary arterial banding. Life Sci 1999;65:925-933.
5. Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin YJ et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007;446:444-448.
6. Tsukamoto O, Minamino T, Okada K, Shintani Y, Takashima S, Kato H et al. Depression of proteasome activities during the progression of cardiac dysfunction in pressure-overloaded heart of mice. Biochem Biophys Res Commun 2006;340:1125-1133.
7. Leri A, Liu Y, Malhotra A, Li Q, Stiegler P, Claudio PP et al. Pacing-induced heart failure in dogs enhances the expression of p53 and p53-dependent genes in ventricular myocytes. Circulation 1998;97:194-203.
8. Leri A, Franco S, Zacheo A, Barlucchi L, Chimenti S, Limana F et al. Ablation of telomerase and telomere loss leads to cardiac dilatation and heart failure associated with p53 upregulation. EMBO J 2003;22:131-139.
9. Narula J, Pandey P, Arbustini E, Haider N, Narula N, Kolodgie FD et al. Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc Natl Acad Sci USA 1999;96:8144-8149.
10. Kostin S, Pool L, Elsasser A, Hein S, Drexler HCA, Arnon E et al. Myocytes die by multiple mechanisms in failing human hearts. Circ Res 2003;92:715-724.
11. van Empel VPM, Bertrand ATA, Hofstra L, Crijns HJ, Doevendans PA, De Windt LJ. Myocyte apoptosis in heart failure. Cardiovasc Res 2005;67:21-29.
12. Sakahira H, Enari M, Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 1998;391:96-99.
13. Widlak P, Garrard WT. Discovery, regulation, and action of the major apoptotic nucleases DFF40/CAD and endonuclease G. J Cell Biochem 2005;94:1078-1087.
14. Merkle S, Frantz S, Schon MP, Bauersachs J, Buitrago M, Frost RJA et al. A role for caspase-1 in heart failure. Circ Res 2007;100:645-653.
15. Wencker D, Chandra M, Nguyen K, Miao WF, Garantziotis S, Factor SM et al. A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 2003;111:1497-1504.
16. Elsasser A, Suzuki K, Schaper J. Unresolved issues regarding the role of apoptosis in the pathogenesis of ischemic injury and heart failure. J Mol Cell Cardiol 2000;32:711-724.
17. Kang PM, Izumo S. Apoptosis and heart failure: a critical review of the literature. Circ Res 2000;86:1107-1113.
18. Takernura G, Fujiwara H. Morphological aspects of apoptosis in heart diseases. J Cell Mol Med 2006;10:56-75.
19. Haider N, Narula N, Narula J. Apoptosis in heart failure represents programmed cell survival, not death, of cardiomyocytes and likelihood of reverse remodeling. J Card Fail 2002;8:S512-S517.
20. Narula J, Haider N, Arbustini E, Chandrashekhar Y. Mechanisms of disease: apoptosis in heart failure - seeing hope in death. Nat Clin Pract Cardiovasc Med 2006;3:681-688.
21. Latif N, Khan MA, Birks E, O'Farrell A, Westbrook J, Dunn MJ et al. Upregulation of the Bcl-2 family of proteins in end stage heart failure. J Am Coll Cardiol 2000;35:1769-1777.
22. Koda M, Takemura G, Kanoh M, Hayakawa K, Kawase Y, Maruyama R et al. Myocytes positive for in situ markers for DNA breaks in human hearts which are hypertrophic, but neither failed nor dilated: a manifestation of cardiac hypertrophy rather than failure. J Path 2003;199:229-236.
23. Kanoh M, Takemura G, Misao J, Hayakawa Y, Aoyama T, Nishigaki K et al. Significance of myocytes with positive DNA in situ nick end-labeling (TUNEL) in hearts with dilated cardiomyopathy: not apoptosis but DNA repair. Circulation 1999;99:2757-2764.
24. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002;82:373-428.
25. Fang SY, Jensen JP, Ludwig RL, Vousden KH, Weissman AM. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 2000;275:8945-8951.
26. Yang YL, Li CCH, Weissman AM. Regulating the p53 system through ubiquitination. Oncogene 2004;23:2096-2106.
27. Toth A, Nickson P, Qin LL, Erhardt P. Differential regulation of cardiomyocyte survival and hypertrophy by MDM2, an E3 ubiquitin ligase. J Biol Chem 2006;281:3679-3689.
28. Li MY, Chen DL, Shiloh A, Luo JY, Nikolaev AY, Qin J et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 2002;416:648-653.
29. Borodovsky A, Ovaa H, Kolli N, Gan-Erdene T, Wilkinson KD, Ploegh HL et al. Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme. Chem Biol 2002;9:1149-1159.
30. Powell SR, Davies KJA, Divald A. Optimal determination of heart tissue 26S-proteasome activity requires maximal stimulating ATP concentrations. J Mol Cell Cardiol 2007;42:265-269.
31. Balasubramanian S, Mani S, Shiraishi H, Johnston RK, Yamane K, Willey CD et al. Enhanced ubiquitination of cytoskeletal proteins in pressure overloaded myocardium. is accompanied by changes in specific E3 ligases. J Mol Cell Cardiol 2006;41:669-679.
32. Foo RSY, Chan LKW, Kitsis RN, Bennett MR. Ubiquitination and degradation of the anti-apoptotic protein ARC by MDM2. J Biol Chem 2007;282:5529-5535.
33. Hamada H, Suzuki M, Yuasa S, Mimura N, Shinozuka N, Takada Y et al. Dilated cardiomyopathy caused by aberrant endoplasmic reticulum quality control in mutant KDEL receptor transgenic mice. Mol Cell Biol 2004;24:8007-8017.
34. Chen QH, Liu JB, Horak KM, Zheng HQ, Kumarapeli ARK, Li J et al. Intrasarcoplasmic amyloidosis impairs proteolytic function of proteasomes in cardiomyocytes by compromising substrate uptake. Circ Res 2005;97:1018-1026.
35. Liu JB, Chen QH, Huang W, Horak KM, Zheng HQ, Mestril R et al. Impairment of the ubiquitin-proteasome system in desminopathy mouse hearts. FASEB J 2005;19:362.
36. Li HH, Kedar V, Zhang CL, McDonough H, Arya R, Wang DZ et al. Atrogin-1/rnuscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J Clin Invest 2004;114:1058-1071.
37. Eble DM, Spragia ML, Ferguson AG, Samarel AM. Sarcomeric myosin heavy chain is degraded by the proteasome. Cell Tissue Res 1999;296:541- 548.
38. Sakahira H, Enari M, Nagata S. Functional differences of two forms of the inhibitor of caspase-activated DNase, ICAD-L, and ICAD-S. J Biol Chem 1999;274:15740-15744.
39. Gu JJ, Dong RP, Zhang CH, McLaughlin DF, Wu MX, Schlossman SF. Functional interaction of DFF35 and DFF45 with caspase-activated DNA fragmentation nuclease DFF40. J Biol Chem 1999;274:20759-20762.